MARKET

MDXG

MDXG

Mimedx Group Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.830
+0.230
+6.39%
After Hours: 3.830 0 0.00% 16:02 05/27 EDT
OPEN
3.570
PREV CLOSE
3.600
HIGH
3.833
LOW
3.510
VOLUME
436.30K
TURNOVER
0
52 WEEK HIGH
15.99
52 WEEK LOW
3.270
MARKET CAP
434.14M
P/E (TTM)
-22.8384
1D
5D
1M
3M
1Y
5Y
MiMedx Says Glass Lewis Recommends in Favor of Director Nominees, Say-on-Pay Proposal
MT Newswires · 05/20 10:19
BRIEF-Mimedx Group Inc - Co Urges Shareholders To Vote "For" Director Nominees - James L. Bierman & Phyllis Gardner, M.D. - On White Proxy Card
reuters.com · 05/18 21:56
MiMedx Group Files Proxy Statement Related To 2022 Annual Shareholder Meeting
Decisive, Positive Actions Taken to Stabilize and Transform MIMEDX Have Established Strong, New Foundation for Growth Company Urges Shareholders to Vote “FOR” Both Highly Qualified Director Nominees
Benzinga · 05/18 20:20
MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation
Decisive, Positive Actions Taken to Stabilize and Transform MIMEDX Have Established Strong, New Foundation for Growth Company Urges Shareholders to Vote “FOR” Both Highly Qualified Director Nominees – James L. Bierman and Phyllis Gardner, M.D. – on the WHI...
GlobeNewswire · 05/18 20:18
Prescience Point Capital Management Calls on MiMedx to Confirm the Company Has Received Letters of Serious Concern from other Shareholders
Prescience Point Capital Management LLC ("Prescience Point"), a research-focused, catalyst-driven investment firm that beneficially owns approximately 6.7% of the outstanding common stock of MiMedx Group, Inc. ("MDXG" or the "Company") (NASDAQ: MDXG), toda...
PR Newswire · 05/18 12:55
MIMEDX Issues Letter To Shareholders
Highlights Successful Execution of Transformation Strategy Under CEO Tim Wright Reaffirms Commitment to Enhancing Value for ALL Shareholders Urges Shareholders to Vote “FOR” Both of MIMEDX’s Highly
Benzinga · 05/16 12:17
BRIEF-Mimedx Mails Letter To Shareholders
reuters.com · 05/16 12:11
MIMEDX Mails Letter to Shareholders
Highlights Successful Execution of Transformation Strategy Under CEO Tim Wright Reaffirms Commitment to Enhancing Value for ALL Shareholders Urges Shareholders to Vote “FOR” Both of MIMEDX’s Highly Qualified Director Nominees – James L. Bierman and Phyllis...
GlobeNewswire · 05/16 12:00
More
No Data
Learn about the latest financial forecast of MDXG. Analyze the recent business situations of Mimedx Group Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MDXG stock price target is 14.17 with a high estimate of 23.00 and a low estimate of 8.50.
High23.00
Average14.17
Low8.50
Current 3.830
EPS
Actual
Estimate
-0.09-0.06-0.04-0.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 169
Institutional Holdings: 65.62M
% Owned: 57.89%
Shares Outstanding: 113.35M
TypeInstitutionsShares
Increased
42
3.76M
New
14
316.44K
Decreased
41
1.69M
Sold Out
18
651.56K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
M. Kathleen Behrens Wilsey
Chief Executive Officer/Director
Timothy Wright
Chief Financial Officer/Executive Vice President - Finance
Peter Carlson
Corporate Executive
Rohit Kashyap
Corporate Executive
Robert Stein
Senior Vice President/Chief Compliance Officer
Mark Graves
Senior Vice President
Scott Turner
Chief Administrative Officer/General Counsel
William Hulse
Independent Director
James Bierman
Independent Director
Phyllis Gardner
Independent Director
Michael Giuliani
Independent Director
William Hawkins
Independent Director
Cato Laurencin
Independent Director
K. Todd Newton
Independent Director
Martin Sutter
No Data
No Data
About MDXG
MiMedx Group, Inc. is utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts for multiple sectors of healthcare. The Company is focused on addressing the needs of patients with acute and chronic non-healing wounds, and a late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. The Company’s platform technologies include AmnioFix, EpiFix, EpiCord, AmnioCord and AmnioFill. Its AmnioFix and EpiFix are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. The EpiCord and AmnioCord are tissue allografts derived from umbilical cord tissue. Its AmnioFill is a particulate product comprised of placental connective tissue matrix, derived from the placental disc and placental membranes.

Webull offers kinds of MiMedx Group Inc stock information, including NASDAQ:MDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDXG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDXG stock methods without spending real money on the virtual paper trading platform.